c-Jun expression was reduced in the excised tumors of all patients injected and tumor depth decreased in the majority. This was the first report of the clinical use of a DNAzyme.
The study found that c-Jun expression was reduced in the removed tumors from all patients who received treatment, and tumor depth decreased in most cases. This marked the initial application of a DNAzyme in clinical settings.